Compare FMNB & MGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | MGTX |
|---|---|---|
| Founded | 1887 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 839.7M | 909.1M |
| IPO Year | 2010 | 2018 |
| Metric | FMNB | MGTX |
|---|---|---|
| Price | $14.39 | $11.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.00 | ★ $24.57 |
| AVG Volume (30 Days) | 387.0K | ★ 761.4K |
| Earning Date | 04-22-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | 18.85 | ★ 33.02 |
| EPS | ★ 0.36 | N/A |
| Revenue | ★ $279,922,000.00 | $81,391,000.00 |
| Revenue This Year | $52.63 | $141.38 |
| Revenue Next Year | $8.28 | N/A |
| P/E Ratio | $39.58 | ★ N/A |
| Revenue Growth | 3.89 | ★ 144.57 |
| 52 Week Low | $12.23 | $6.31 |
| 52 Week High | $15.50 | $11.85 |
| Indicator | FMNB | MGTX |
|---|---|---|
| Relative Strength Index (RSI) | 55.73 | 71.91 |
| Support Level | $13.71 | $7.10 |
| Resistance Level | $14.68 | $11.85 |
| Average True Range (ATR) | 0.24 | 0.59 |
| MACD | -0.01 | 0.25 |
| Stochastic Oscillator | 72.56 | 94.85 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.